Mon - Fri 09:00-18:00 0207 060 3773
Email info@boundarycapital.com

Blog

Dymag launches new BOXSTROMTM carbon hybrid auto wheel

Boundary investee Dymag has launched its new BOXSTROMTM carbon hybrid auto wheel aimed at OEMs and the aftermarket in early November. The wheel is typically 40% lighter than standard cast wheels and 25% lighter than forged wheels yet fully meets the relevant testing standards. To achieve this Dymag developed several patent-pending innovations for the new […]

Boundary partners with Yati Capital to open investment opportunities from India

Boundary has partnered with advisers Yati Capital, to create investment streams from India and provide geographic reach to portfolio companies. Boundary has already secured additional investment as a result of the new partnership into their AngelPlus Fund, from Indian entrepreneur Rajneesh Bhandari. Rajneesh Bhandari is a first generation serial entrepreneur and has promoted four successful ventures in Telecommunication, […]

Case study: Desktop Genetics

Gene editing is one of hottest areas of life sciences. Many scientists are working towards using CRISPR technology to provide genetic solutions to conditions by literally editing the DNA in the genes. Desktop Genetics provides gene editing software (SaaS and on-prem) to make CRISPR gene editing easy and cost-effective. With their platform, DESKGEN, scientists can […]

Boundary Capital invests in Disruptive Antimicrobial Technology

Boundary Capital has announced its latest investment in Toxibact, a disruptive technology which has the potential to kill a wide range of microorganisms including bacteria and fungi with little prospect of them being able to develop resistance. Toxibact has a novel potential antimicrobial therapy for the treatment of all bacteria – both ‘gram positive’ and […]

Boundary Capital invests in Ground-breaking Alzheimer’s Therapeutic Technology

Boundary Capital has announced its latest investment in AB-Polyblok, a revolutionary technology which has the potential to treat, and potentially partially reverse, the effects of Alzheimer’s Disease. AB-Polyblock has a novel potential drug therapy for the treatment of Alzheimer’s Disease. The drug was conceived and developed after independent, private research. Alzheimer’s Disease is the largest […]

Boundary Capital in the Press: EIS Magazine

Boundary Capital is featured in this month’s issue of EIS Magazine discussing the pros and cons of Crowdfunding… Crowdfunding: Where Angels Fear to Tread? Dan Somers, Managing Partner at London-based Boundary Capital Partners, says that crowdfunding is a phenomenon of our age: “Whilst most crowdfunding is debt-based, UK equity crowdfunding (our focus here) rose from […]